Structure Therapeutics (GPCR) financial statements
Net income was -$141M.
Free cash flow was -$226M.
The diluted share count rose 1753% over the period (dilution).
Income statement
Fiscal years, from Structure Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Research and development | $36M | $70M | $109M | $225M |
| Selling, general and admin | $16M | $33M | $49M | $62M |
| Operating income | -$53M | -$103M | -$158M | -$177M |
| Pre-tax income | -$51M | -$89M | -$122M | -$141M |
| Income tax | $17,000 | $236,000 | $310,000 | $515,000 |
| Net income | -$51M | -$90M | -$123M | -$141M |
| EPS (diluted) | -$5.51 | -$0.81 | -$0.78 | -$0.80 |
| Diluted shares | 10M | 110M | 158M | 178M |
Balance sheet
Fiscal years, from Structure Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $91M | $467M | $884M | $1.4B |
| Total current assets | $93M | $474M | $891M | $1.6B |
| Property, plant and equipment | $1M | $3M | $3M | $7M |
| Total assets | $98M | $482M | $903M | $1.6B |
| Total current liabilities | $13M | $25M | $36M | $63M |
| Total liabilities | $13M | $29M | $38M | $68M |
| Shareholders' equity | -$115M | $453M | $865M | $1.5B |
| Net debt | -$26M | -$130M | -$170M | -$800M |
Cash flow
Fiscal years, from Structure Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -$46M | -$79M | -$117M | -$222M |
| Capital spending | $155,000 | $2M | $1M | $4M |
| Free cash flow | -$46M | -$82M | -$118M | -$226M |
| Stock-based compensation | $3M | $8M | $19M | $29M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GPCR.
Open GPCR in InvestinglyQuestions
How much free cash flow does Structure Therapeutics generate?
-$226M in fiscal 2025 (operating cash flow minus capital spending).
From Structure Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.